# EDGAR Filing Document

**Accession Number:** 0001756655
**File Stem:** 0001628280-26-046247
**Filing Date:** 2026-6
**Character Count:** 7161
**Document Hash:** c68923f88b56743d3af9e2ca84a9fe01
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-046247.hdr.sgml**: 20260630

**ACCESSION NUMBER**: 0001628280-26-046247

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260626

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260630

**DATE AS OF CHANGE**: 20260630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ardent Health, Inc.
- **CENTRAL INDEX KEY:** 0001756655
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 611764793
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42180
- **FILM NUMBER:** 261140978

**BUSINESS ADDRESS:**
- **STREET 1:** 340 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 100
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027
- **BUSINESS PHONE:** 6152963000

**MAIL ADDRESS:**
- **STREET 1:** 340 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 100
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ardent Health Partners, Inc.
- **DATE OF NAME CHANGE:** 20240717

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ardent Health Partners, LLC
- **DATE OF NAME CHANGE:** 20181022

?xml version='1.0' encoding='ASCII'? ardt-20260626

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 30, 2026 (June 26, 2026)**

---

| |
|:---|
| **ARDENT HEALTH, INC.** |
| **(Exact Name of Registrant as Specified in its Charter)** |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42180** | **61-1764793** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
| **340 Seven Springs Way, Suite 100,** <br>**Brentwood, Tennessee** |  | **37027** |
| (Address of Principal Executive Offices) |  | (Zip Code) |
|  | **(615) 296-3000** |  |
| (Registrant's Telephone Number, including Area Code) | (Registrant's Telephone Number, including Area Code) | (Registrant's Telephone Number, including Area Code) |
|  | **Not Applicable** |  |
| (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common Stock, $.01 par value per share | ARDT | New York Stock Exchange |

---

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. &nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously disclosed, on June 2, 2026 (the "Effective Date"), Ardent Health, Inc. (the "Company") announced that Martin J. Bonick had departed from his role as President and Chief Executive Officer of the Company and had stepped down from the Company's Board of Directors (the "Board"), effective as of the Effective Date.

In connection with Mr. Bonick's departure from his role as President and Chief Executive Officer of the Company, on June 26, 2026, Mr. Bonick and an affiliate of the Company entered into a separation agreement and general release, effective as of the Effective Date (the "Separation Agreement").

Pursuant to the Separation Agreement, Mr. Bonick will receive certain severance benefits that are consistent with a termination of employment by the Company without "Cause" (as defined in Mr. Bonick's employment agreement with the Company), as described in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 8, 2026, subject to his non-revocation of the Separation Agreement and the release of claims contained in the Separation Agreement. The Separation Agreement also provides that the vesting and/or forfeiture of Mr. Bonick's time-based restricted stock units, performance-based restricted stock units and shares of restricted stock will be governed by the terms of the Company's incentive award plan and Mr. Bonick's award agreements granted thereunder. Under the Separation Agreement, Mr. Bonick is subject to non-competition and non-solicitation covenants for twelve months following the Effective Date.

The foregoing description of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits:

---

| | |
|:---|:---|
| <br>**Exhibit No.** | <br>**Exhibit Description** |
| 10.1 | <u>[Separation Agreement and General Release, date](ex101-separationrelease.htm)[d](ex101-separationrelease.htm)[as of June 26, 2026, by and between AHS Management Company, Inc. and Martin J. Bonick](ex101-separationrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: June 30, 2026 | **ARDENT HEALTH, INC.** | **ARDENT HEALTH, INC.** |
|  | By: | */s/ Stephen C. Petrovich* |
|  | Name: | Stephen C. Petrovich |
|  | Title: | Executive Vice President & General Counsel |

---